These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 25521397

  • 1. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
    Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH, Welch JJ, Korn EL, Ullmann CD, Hirsch FR.
    J Thorac Oncol; 2014 Oct; 9(10):1443-8. PubMed ID: 25521397
    [Abstract] [Full Text] [Related]

  • 2. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [Abstract] [Full Text] [Related]

  • 3. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
    Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.
    J Thorac Oncol; 2018 Nov; 13(11):1655-1667. PubMed ID: 30266660
    [Abstract] [Full Text] [Related]

  • 4. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 5. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM, Boerner SA, Seymour L.
    Clin Cancer Res; 2010 Mar 15; 16(6):1710-8. PubMed ID: 20215546
    [Abstract] [Full Text] [Related]

  • 6. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
    Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative.
    Clin Cancer Res; 2010 Jul 01; 16(13):3299-318. PubMed ID: 20501613
    [Abstract] [Full Text] [Related]

  • 7. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR, Biomarkers Task Force of the NCI Investigational Drug Steering Committee.
    Clin Cancer Res; 2010 Mar 15; 16(6):1745-55. PubMed ID: 20215558
    [Abstract] [Full Text] [Related]

  • 8. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology.
    J Clin Oncol; 2003 Jun 15; 21(12):2377-86. PubMed ID: 12721281
    [Abstract] [Full Text] [Related]

  • 9. Master protocols in lung cancer: experience from Lung Master Protocol.
    Lam VK, Papadimitrakopoulou V.
    Curr Opin Oncol; 2018 Mar 15; 30(2):92-97. PubMed ID: 29329112
    [Abstract] [Full Text] [Related]

  • 10. The NCI All Ireland Cancer Conference.
    Johnston PG, Daly PA, Liu E.
    Oncologist; 1999 Mar 15; 4(4):275-277. PubMed ID: 10545862
    [Abstract] [Full Text] [Related]

  • 11. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 15; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 12. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K, O'Sullivan Coyne G, Chen AP.
    Chin Clin Oncol; 2015 Sep 15; 4(3):31. PubMed ID: 26408298
    [Abstract] [Full Text] [Related]

  • 13. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
    Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.
    J Transl Med; 2009 Jun 17; 7():45. PubMed ID: 19534815
    [Abstract] [Full Text] [Related]

  • 14. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
    Hall JA, Salgado R, Lively T, Sweep F, Schuh A.
    Lancet Oncol; 2014 Apr 17; 15(4):e184-93. PubMed ID: 24694642
    [Abstract] [Full Text] [Related]

  • 15. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.
    Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM.
    J Natl Cancer Inst; 2009 Apr 15; 101(8):554-9. PubMed ID: 19351920
    [Abstract] [Full Text] [Related]

  • 16. Regulatory Forum commentary: through the looking glass--SENDing the pathology data we have INHAND.
    Keenan CM, Goodman DG.
    Toxicol Pathol; 2014 Jul 15; 42(5):807-10. PubMed ID: 23599411
    [Abstract] [Full Text] [Related]

  • 17. Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective.
    Petrick N, Brown DG, Suleiman O, Myers KJ.
    Clin Pharmacol Ther; 2008 Oct 15; 84(4):523-5. PubMed ID: 18716616
    [Abstract] [Full Text] [Related]

  • 18. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
    Lefer DJ, Bolli R.
    J Cardiovasc Pharmacol Ther; 2011 Oct 15; 16(3-4):332-9. PubMed ID: 21821536
    [Abstract] [Full Text] [Related]

  • 19. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
    Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, Govindan R.
    J Thorac Oncol; 2013 Jul 15; 8(7):860-5. PubMed ID: 23478543
    [Abstract] [Full Text] [Related]

  • 20. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
    Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS.
    Neuro Oncol; 2016 Mar 15; 18 Suppl 2(Suppl 2):ii26-ii36. PubMed ID: 26989130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.